Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Giles FJ, et al. Among authors: fan x. Leukemia. 2013 Jan;27(1):107-12. doi: 10.1038/leu.2012.181. Epub 2012 Jul 5. Leukemia. 2013. PMID: 22763385 Clinical Trial.
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Hochhaus A, et al. Among authors: fan x. Blood. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. Epub 2013 Mar 15. Blood. 2013. PMID: 23502220 Free PMC article. Clinical Trial.
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Hochhaus A, et al. Among authors: fan x. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. doi: 10.1007/s00432-013-1529-7. Epub 2013 Sep 22. J Cancer Res Clin Oncol. 2013. PMID: 24057647 Free PMC article. Clinical Trial.
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Hughes TP, et al. Among authors: fan x. Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11. Blood. 2014. PMID: 24335106 Free PMC article. Clinical Trial.
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Hughes TP, et al. Among authors: fan x. Haematologica. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. Epub 2014 Feb 14. Haematologica. 2014. PMID: 24532039 Free PMC article. Clinical Trial.
Importance of oxalic acid to antioxidation and detoxification in M. oryzae, not to pathogenicity in M.OryzaeDecarboxylase mediated oxalic acid metabolism is important to antioxidation and detoxification rather than pathogenicity in magnaporthe oryzae.
Liu C, Wei Y, Dang Y, Batool W, Fan X, Hu Y, He Z, Zhang S. Liu C, et al. Among authors: fan x. Virulence. 2025 Jan 15:2444690. doi: 10.1080/21505594.2024.2444690. Online ahead of print. Virulence. 2025. PMID: 39814555 Free article.
Definition for consensus statement much needed.
Fan X, Tham CC, Leung CKS, Jonas JB. Fan X, et al. Asia Pac J Ophthalmol (Phila). 2025 Jan 13:100141. doi: 10.1016/j.apjo.2025.100141. Online ahead of print. Asia Pac J Ophthalmol (Phila). 2025. PMID: 39814142 No abstract available.
16,168 results
You have reached the last available page of results. Please see the User Guide for more information.